KRAS and neuroendocrine carcinoma: The results from the molecular profiling revealed specific genomic signatures for pancreatic (MEN1, ATRX, and CREBBP), midgut (CDKN1B) NETs, and GEP-NEC (TP53, RB1, KRAS, CSMD3, TRRAP, and MYC) [59,60].